PDOHub Precision Organoids
Asia’s Organoid Precision Medicine Hub
PDOHub™ Hong Kong is the Asia’s First Integrated Organoid‑Based Precision Medicine Centre, established by our CVVT and startup company BiomOrgan to bring advanced organoid technology into real‑world applications. We serve as a dedicated hub for developing, validating, and deploying patient‑derived organoid (PDO) platforms across oncology, infectious diseases, and emerging health challenges.
Tumour Organoid Drug Sensitivity Test
A new way to guide personalised treatment
What is Tumour Organoid Drug Sensitivity Test?
Tumour Organoid Drug Sensitivity Test uses proprietary organoid technology to test how the patient’s tumour cells respond to a panel of oncology drugs in their tumour organoids. Since tumour organoid physiologically and genetically simulates the original tumour, the drug testing results will assist the medical practitioner in formulating personalized treatment strategies.
How it Works
-
Biopsy & Tissue Collection
A small portion of the patient’s tumour tissue is collected during surgery or a routine biopsy. Malignant body fluid is also acceptable.
-
Growing Tumour Organoids
The patient’s tumour organoids are grown in the laboratory and prepared for drug testing.
-
Testing Drug Responses
The grown tumour organoids are exposed to various cancer drugs in culture, and their response to each drug is measured in the laboratory.
-
Delivering Personalized Treatment Insights
A report summarizing the tumour organoid drug sensitivity is shared with the oncologist, who will review it alongside the patient’s clinical history to help guide a personalized treatment plan.
Applications Across Solid Tumours
-
GI Cancers
Optimizing chemotherapy and targeted regimens for colorectal, gastric, and pancreatic malignancies via patient-specific drug response profiling.
-
Lung Cancer
Evaluating standard-of-care and novel TKI responses in NSCLC, bridging the gap between genomic data and functional outcomes.
-
Breast CancerRefining therapeutic selection for TNBC and advanced cases, including sensitivity testing for ADCs.
-
Other Solid Tumours
Providing evidence‑based phenotypic insights for other solid tumours, including head and neck cancers, esophageal cancer, liver cancer, bladder cancer, sarcoma, and others.
Please visit PDOHub website to learn more:
